We help companies optimise R&D investment and ‘go/no-go’ decisions by assessing early-stage pipeline potential. This includes in-depth qualitative and quantitative evaluation of portfolio assets driven by first-class analysis and commercial expertise.
Bull & Bear Life Sciences were approached by a global clinical-stage biotechnology company with a strong pipeline of rare disease assets (at different developmental stages), to build out a range of simulations to inform portfolio strategy. Drug development requires significant upfront investment so identifying ways to maximise opportunity via effective resource allocation is crucial.
Working cross-functionally with key Marketing, Clinical and Market Access stakeholders, we modelled the interplay between assets and presented a range of options, highlighting areas of high potential and strong opportunity. With this information, senior management were able to identify next development steps for the pipeline, including the potential for a fixed dose combination.
Portfolio strategy is crucial when managing a range of assets across various stages of development. Our consultants collaborate with cross-functional teams to provide first-class modelling, simulation and commercial insight within client portfolios from early stage and pre-launch through to loss of exclusivity, enabling clients to make key strategic decisions.
We help companies optimise R&D investment and ‘go/no-go’ decisions by assessing early-stage pipeline potential.
We assist companies in maximising product value by assessing potential options for geographical expansion, and optimal operating and commercial structures.
We collaborate with companies to enhance value across the in-market lifecycle, from early launch phase through to LOE. Our vast experience in strategic planning, forecasting and commercial leadership enables us to ask key strategic questions while providing high quality analysis and recommendations.
Combining strong experience and expertise in financial advisory and life sciences, we are able to advise clients across all stages of the deal cycle, including commercial assessments, acquisitions, in-licensing and out-licensing.
Portfolio strategy is crucial when managing a range/class of assets. Our consultants collaborate with cross-functional teams to provide first-class modelling and simulation of client portfolios from early stage/pre-launch through to loss of exclusivity, driving key strategic decisions.
We help companies optimise R&D investment and ‘go/no-go’ decisions by assessing overall early-stage pipeline potential. This includes in-depth qualitative and quantitative evaluation of portfolio assets driven by first-class analysis and commercial expertise.
We assist companies in maximising product value whether at late-stage development or product launch, by assessing various options for geographical expansion, optimal operating and commercial structures, while maintaining focus on maximising profitability and ROI.
We collaborate with companies in enhancing value across the in-market lifecycle, from early launch/growth phase through to LOE. Our vast experience in strategic planning, forecasting and commercial leadership enables us to ask key strategic questions while providing high quality analysis and recommendations.
Combining strong experience and expertise in financial advisory and life sciences, we are able to advise clients across all stages of the deal cycle, including commercial assessments, acquisitions, in-licensing and out-licensing.
